TABLE 3.
Efficacies of eravacycline and comparators in a neutropenic mouse thigh model
| Strain | Antibiotic | i.v. dose (mg/kg) providing the following CFU reduction from untreated controls at 24 h posttreatment: |
Maximum log10 CFU reduction (dose in mg/kg) | ||
|---|---|---|---|---|---|
| 1 log10 | 2 log10 | 3 log10 | |||
| S. aureus ATCC 13709 | Eravacycline | 0.2 | 0.2 | 0.4 | 5.1 (10) |
| Tigecycline | 1.2 | 1.5 | 2 | 4.8 (30) | |
| S. aureus SA161 MRSA [tet(M)] | Eravacycline | 0.6 | 1 | 3 | 3.5 (10) |
| Tigecycline | 3 | 12.5 | 17.3 | 3.6 (20) | |
| Vancomycin | 0.8 | 2.9 | 10 | 3.5 (30) | |
| S. aureus SA192 MRSA [tet(M), USA300] | Eravacycline | 3.5 | 9.5 | NAa | 2.1 (10) |
| Tigecycline | 3.8 | 8 | NA | 2.9 (20) | |
| Vancomycin | 2.1 | 19.2 | NA | 2.8 (30) | |
| S. aureus SA158 [tet(K)] | Eravacycline | 2.3 | 8.2 | 16.2 | 3.5 (20) |
| Tigecycline | 2.1 | 5.4 | 9.7 | 3.2 (20) | |
| Vancomycin | 2.8 | >20 | >20 | 1.7 (20) | |
| S. pyogenes ATCC 8668 | Eravacycline | 5.3 | 9 | NA | 2.3 (10) |
| Tigecycline | 6 | 15.8 | NA | 2.3 (20) | |
| Linezolid | >20 | >20 | NA | 0.7 (20) | |
a
NA, not applicable.